Home » Newsletters » BioWorld Science

BioWorld Science

March 25, 2011

View Archived Issues

New protein kinase inhibitors patented by Cylene Pharmaceuticals

Novel series of vasopressin receptor antagonists presented by Bayer

Karus Therapeutics presents new PI3K inhibitors

Arisaph Pharmaceuticals receives FDA IND approval for first-in-human study of ARI-3037-MO

Novel deuterated voltage-gated calcium channel blockers patented by Merck & Co.

Levels of Kit ligand in the serum described as possible biomarker for AIU

Results from phase I/II trial of MDV-3100 in CRPC reveal long-term efficacy

Two phase III studies demonstrate the efficacy of mirabegron in overactive bladder

Phase III study results detailed for abiraterone acetate in metastatic CRPC

Abbott synthesizes new lysophospholipid receptor agonists for cognition disorders

Novel B-raf kinase inhibitors presented by Novartis

GSK patents novel orexin receptor antagonists for sleep disorders

Omeros' phase IIb study of OMS-302 meets coprimary endpoints in cataract surgery

Genesis Biopharma develops active immunotherapy platform for cancer

Nordion cleared to begin two phase III TheraSphere trials in cancer

Merck & Co. receives FDA approval for expanded age indication for Zostavax

Oncolytics Biotech completes enrollment in phase II Reolysin trial in head and neck cancers

Targacept's TC-5619 misses primary endpoint in phase II proof-of-concept trial for ADHD

Stemedica treats first subject in phase I/II study of ischemic allogeneic mesenchymal stem cells

Vectura's VR-496 shows anti-inflammatory activity in phase II cystic fibrosis trial

CHMP recommends new indication for Herceptin in early breast cancer

Rockwell Medical begins enrollment in pivotal phase III study of continuous iron therapy SFP

Oramed Pharmaceuticals completes toxicity study for oral insulin capsule

Pozen reports positive results for PA-32540 in healthy subjects

FDA approves Gel-One for pain associated with osteoarthritis of the knee

Cilag to market Pozen's antimigraine treatment MT-400 in parts of South America

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...